AcquisitionOther
CONDUIT PHARMACEUTICALS INC. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
CONDUIT PHARMACEUTICALS INC. -> target · $4.4 million
Our current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection.
Open source record (SEC) ↗